Navigation Links
Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program
Date:8/25/2008

NYON, Switzerland, August 25 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB:MYMX) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Mymetics Corporation will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Mymetics have further contracted with BlueSkyMLS http://www.blueskymls.com to seek registration in states not covered by the S&P Market Access Program.

Ernest Luebke, Chief Financial Officer of Mymetics Corporation stated "We are very pleased with the level of professionalism demonstrated by Standard & Poor's as well as BlueSkyMLS in assisting us with our US exemption process."

About Mymetics Corporation

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.

Contacts:

Anthony Jessop

Senior Vice President Mymetics, Inc.

tel: North America +1-303-800-6606

ajessop@mymetics.com

Standard & Poor's Customer Contact:

Richard Albanese

+1-212-438-3647

richard_albanese@sandp.com

Standard and Poor's Media Relations Contact:

Michael Privitera

+1-212-438-6679

michael_privitera@sandp.com

BlueSkyMLS Contact :

Theodore J. Dragon

+1-201-804-3909 x 113

tdragon@blueskymls.com


'/>"/>
SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mymetics Corporation Important Shareholders Information Conference Call
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
3. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains ... strain on health care systems, in terms of costs and ... too does the development of innovative and efficient therapies that ... the many types of cancer treatments, a growing number of ...
(Date:3/23/2017)...  Agriculture technology company Cool Planet has closed on ... to commercialize its Cool Terra and Cool Fauna Engineered ... that are simultaneously profitable as well as sustainable and ... months. This latest round of funding was led by ... The company,s primary product, Cool Terra, can improve ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):